Priaxon AG L., formerly based in Munich, Germany, discovered and developed small molecule therapeutics for novel target-ligand interactions. Proprietary, highly versatile chemo-informatics tools rapidly identified essential molecular determinants of novel target-ligand interactions, and applied this information to select suitable ligand motifs in previously unexplored chemical space.

Our company goal was to demonstrate the superior efficiency in terms of innovation, timelines and R&D economics of applying Priaxon’s tools to the rapid evaluation and NCE based exploitation of new drug targets.

Combined, the Priaxplore® tools provided for rapid initial in silico hit prediction, reduced synthetic chemistry workload and focused hit screening campaigns of pre-optimised molecular entities with novel chemotypes. Moreover, the required input for successful application was either target structural information, or the structure of a known ligand, but not necessarily both.

Priaxons R&D approach was truly target-based, and applied similarly to novel drug targets (e.g. PPIs, epigenetic targets), and novel interaction mechanisms on established targets (e.g. allosteric control of kinase activity).

Unlike many competitors’ approaches, it was not restricted to technologies, chemical libraries or assay formats specific to a given target class. On the contrary, potential novel targets could be evaluated for their accessibility and biological impact using rapidly generated, proprietary tool compounds- as soon as structural information is available on either the target or a known modulator.

Proof of the attraction and validity of Priaxons R&D process is constituted by a 2010 early discovery collaboration/license deal with Boehringer Ingelheim on Priaxons NCE inhibitors of the mdm2/p53 interaction. An collaboration with GlaxoSmithKline (GSK) on an undisclosed ion channel PPI target of relevance in CV indications underscored continued Industry interest.